The sales of obstructive airway diseases medicine in Finland demonstrate a steady increase from 2023 onwards, with values expected to rise from 90.9 million Euros in 2024 to 91.3 million Euros in 2028. In 2023, sales stood at 90.8 million Euros. This indicates a very slight year-on-year growth rate of approximately 0.1% each following year, reflecting stability in the market. Over the last two years, the average annual growth rate (CAGR) has been consistent at around 0.1%.
Future trends to watch for include advancements in medical treatments for obstructive airway diseases, potentially impacting the market positively. Additionally, healthcare policy changes, economic conditions, and demographic shifts in Finland could influence future sales dynamics.
